Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
This article was originally published in PharmAsia News
Executive Summary
Emerging markets, the key driver for Reckitt Benckiser's nearly 20 percent net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S
You may also be interested in...
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
Amid Controversy, Reckitt Clinches Paras Brands As India's OTC Drug Market Heats Up
MUMBAI - Outbidding at least six serious rivals, London-headquartered consumer and healthcare products giant Reckitt Benckiser paid a hefty $742 million to clinch the acquisition of India's Paras Pharma - a company that created strong OTC healthcare brands mainly through large-scale mass media campaigns over the last 10 years
Reckitt CFO Day departs
Colin Day, Reckitt Benckiser's chief financial officer for 10 years, will leave the organization, the U.K. company says Oct. 22. Day, who as CFO has seen the firm significantly expand its pharmaceutical business, will remain in the position until March 2011 to ensure a smooth transition. A successor will be announced in the next few months, the firm said